Pharmacare bill offers too much ambiguity and too little ambition
To understand and maximize value, we should know why the government chose this odd-duck model, and diabetes and contraception drugs over others. Politics over public health, perhaps?

For decades, pharmacare has been a day late and a dollar short. How much did Bill C-64 change that?
SPONSORED CONTENT
Get Weekend Point of View Newsletter
A round up of the past week’s opinion writers and columnists on Saturdays and Sundays.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy












